Around seven years after exiting the infectious disease category, Eli Lilly is back – thanks to a trio of acquisitions worth more than $3.8 billion. At a stroke, the deals to acquire Curevo, LimmaTech ...

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout ...

Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of ...

At its second attempt, Gilead Sciences has won FDA approval for chronic hepatitis D virus (HDV) therapy Hepcludex, almost ...

ASCO is just around the corner, and as usual, there is a fertile crop of high-profile clinical trials to look out for among the late-breaker presentations. To follow – and in no particular order - are ...

In a packed programme, the EMA's human medicines committee recommended eight new medicines and 13 line extensions at its May meeting, including Novo Nordisk's oral formulation of GLP-1 agonist Wegovy ...

Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto to include ...

The WHO has held a closed expert meeting to identify potential vaccines for the Bundibugyo species of Ebola that is causing ...

Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle ...

An unsolicited bid by private equity group CVC to take control of Italian pharma company Recordati looks likely to come off, ...

Eli Lilly's triple G agonist retatrutide has achieved weight loss of more than 28% in a new phase 3 trial that keeps it on ...

Two months after saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement ...